<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="seasonally and less frequently (such as in the case of" exact="influenza" post="virus) as pandemic infections. Some of these viruses have"/>
 <result pre="A recent example of these events is the avian-origin H7N9" exact="influenza" post="virus outbreak currently undergoing in China. Human H7N9 influenza"/>
 <result pre="H7N9 influenza virus outbreak currently undergoing in China. Human H7N9" exact="influenza" post="viruses are resistant to amantadines and some strains are"/>
 <result pre="(RSV) may cause a lower respiratory tract infection characterized by" exact="bronchiolitis" post="and pneumonia mainly in children and the elderly. Infection"/>
 <result pre="cause a lower respiratory tract infection characterized by bronchiolitis and" exact="pneumonia" post="mainly in children and the elderly. Infection with RSV"/>
 <result pre="currently under development for the treatment of these infections. antiviral" exact="influenza" post="respiratory syncytial virus MERS-coronavirus novel therapeutic agents Funding NIAID-funded"/>
 <result pre="Among the two leading causes of respiratory virus infection are" exact="influenza" post="(A and B) viruses and the respiratory syncytial virus"/>
 <result pre="and develop severe disease ( Jorquera and Tripp, 2017). While" exact="influenza" post="viruses and RSV circulate seasonally between beginning of fall"/>
 <result pre="beginning of fall and early spring, the increased numbers of" exact="avian influenza" post="(H7N9) in China including highly pathogenic (HP) strains of"/>
 <result pre="of fall and early spring, the increased numbers of avian" exact="influenza" post="(H7N9) in China including highly pathogenic (HP) strains of"/>
 <result pre="strains of the virus, the continued outbreaks of the HP" exact="avian influenza" post="(HPAI) H5N1 viruses, novel variants of seasonal influenza viruses"/>
 <result pre="of the virus, the continued outbreaks of the HP avian" exact="influenza" post="(HPAI) H5N1 viruses, novel variants of seasonal influenza viruses"/>
 <result pre="HP avian influenza (HPAI) H5N1 viruses, novel variants of seasonal" exact="influenza" post="viruses (H3N2var), and the emergence of the Middle East"/>
 <result pre="antivirals. A diagram of the virus life cycle of (A)" exact="influenza" post="virus, (B) respiratory syncytial virus, and (C) Middle East"/>
 <result pre="the availability of successful vaccines and antivirals, infection with seasonal" exact="influenza" post="viruses is still the cause of 3â€“5 million cases"/>
 <result pre="2017). In the US alone, it is estimated that seasonal" exact="influenza" post="affects up to 9 million people a year resulting"/>
 <result pre="of dollars ( Putri et al., 2018). In addition, pandemic" exact="influenza" post="outbreaks emerge at unpredictable intervals causing increased morbidity, mortality,"/>
 <result pre="and Chou, 2008; Ison, 2017). These compounds are specific for" exact="influenza" post="A viruses since the M2 protein of influenza B"/>
 <result pre="specific for influenza A viruses since the M2 protein of" exact="influenza" post="B viruses is structurally different ( Wang et al.,"/>
 <result pre="reported high levels of resistance (&amp;gt;99%) to adamantanes among circulating" exact="influenza" post="A(H3N2) and influenza A(H1N1)pdm09 viruses, and the centers for"/>
 <result pre="of resistance (&amp;gt;99%) to adamantanes among circulating influenza A(H3N2) and" exact="influenza" post="A(H1N1)pdm09 viruses, and the centers for disease control and"/>
 <result pre="these compounds for antiviral treatment or chemoprophylaxis of currently circulating" exact="influenza" post="A viruses ( Centers for Disease Control and Prevention,"/>
 <result pre="oseltamivir, zanamivir, and peramivir is very low in currently circulating" exact="influenza" post="virus strains, although this can change because several clusters"/>
 <result pre="cap-dependent endonuclease, preventing the initiation of mRNA synthesis of the" exact="influenza" post="virus ( Takashita et al., 2018). This is a"/>
 <result pre="is a potent small molecule that shows activity against several" exact="influenza" post="A viruses, including oseltamivir-resistant viruses as well as B"/>
 <result pre="al., 2018). Preclinical studies demonstrated that treated mice infected with" exact="influenza" post="virus were protected from clinical signs and mortality even"/>
 <result pre="et al., 2018). In addition, studies in mice infected with" exact="avian influenza" post="viruses such as H5N1 or H7N9 also demonstrated protection"/>
 <result pre="al., 2018). In addition, studies in mice infected with avian" exact="influenza" post="viruses such as H5N1 or H7N9 also demonstrated protection"/>
 <result pre="with a placebo or oseltamivir in healthy patients infected with" exact="influenza" post="demonstrated that the drug was well tolerated and was"/>
 <result pre="combination with standard-of-care neuraminidase inhibitor in hospitalized participants with severe" exact="influenza" post="(NCT03684044). These studies are currently recruiting and expected to"/>
 <result pre="approved by the FDA for the treatment of acute, uncomplicated" exact="influenza" post="in people aged 12 years and older ( Food"/>
 <result pre="easily administered in uncomplicated as well as complicated cases of" exact="influenza" post="( Koszalka et al., 2017; Shaw, 2017). Next, we"/>
 <result pre="(mAbs) have stimulated the development of novel mAbs-based therapies for" exact="influenza" post="and other infectious diseases ( Jin et al., 2017)."/>
 <result pre="broadly neutralizing mAbs targeting the conserved stalk region of the" exact="influenza" post="virus hemagglutinin (HA) molecule are currently under development. In"/>
 <result pre="of mAbs demonstrated neutralization activity across a broad spectrum of" exact="influenza" post="A subtypes. CR6261 is protective in mice against lethal"/>
 <result pre="region of hemagglutinin. The mAb is active against group 2" exact="influenza" post="viruses and has been shown to have neutralization activity"/>
 <result pre="evaluate the protective efficacy and safety of CR8020 in an" exact="influenza" post="challenge model was completed in 2014 (NCT01938352). Unfortunately, a"/>
 <result pre="and in vivo against different group 1 and group 2" exact="influenza" post="viruses. A phase 2a clinical trial (NCT02071914) was conducted"/>
 <result pre="to evaluate the efficacy and safety of CT-P27 in an" exact="influenza" post="challenge model. The study concluded in July 2014, however"/>
 <result pre="combo in comparison to placebo in subjects with acute uncomplicated" exact="influenza" post="A infection. MEDI8852 This is a potent, broadly neutralizing"/>
 <result pre="protein. MEDI8852 has been reported to effectively neutralize all known" exact="influenza" post="A HA subtypes ( Kallewaard et al., 2016). Preclinical"/>
 <result pre="in animal models have shown efficacy in protecting against H5N1" exact="influenza" post="virus lethal challenges when used alone or in combination"/>
 <result pre="evaluate the safety of MEDI8852 in adults with acute, uncomplicated" exact="influenza" post="was recently concluded and results demonstrated an acceptable safety"/>
 <result pre="HA and is capable of neutralizing all tested seasonal human" exact="influenza" post="A strains ( Nakamura et al., 2013). Two mechanisms"/>
 <result pre="efficacy in the mouse model against a diverse group of" exact="influenza" post="viruses including group 1 and group 2 strains even"/>
 <result pre="(IV) dose of MHAA4549A in adult participants hospitalized with severe" exact="influenza" post="A in combination with oseltamivir was recently concluded and"/>
 <result pre="novel, non-nucleoside polymerase inhibitor that targets the PB2 subunit of" exact="influenza" post="A viruses. Targeting the PB2 avoids docking of the"/>
 <result pre="2015). Furthermore, it is active against a diverse group of" exact="influenza" post="A viruses including the H1N1pdm, H5N1, and H7N9 ("/>
 <result pre="days versus placebo, in adult patients with acute, uncomplicated seasonal" exact="influenza" post="A. Recently, pimodivir has received FDA Fast Track designation"/>
 <result pre="to address an unmet medical need in those who develop" exact="influenza" post="A infection complications. A phase 3 clinical trial (NCT03381196)"/>
 <result pre="T-705, this substituted pyrazinecarboxamide derivative is an inhibitor of the" exact="influenza" post="virus polymerase. As a purine nucleoside analog, favipiravir directly"/>
 <result pre="et al., 2005) and it has broad-spectrum activity against all" exact="influenza" post="subtypes including those resistant to neuraminidase and M2 inhibitors"/>
 <result pre="broad antiviral spectrum of this compound against different human and" exact="avian influenza" post="A and B viruses including avian influenza viruses H5N1"/>
 <result pre="antiviral spectrum of this compound against different human and avian" exact="influenza" post="A and B viruses including avian influenza viruses H5N1"/>
 <result pre="different human and avian influenza A and B viruses including" exact="avian influenza" post="viruses H5N1 and H7N9 ( Sidwell et al., 2007;"/>
 <result pre="human and avian influenza A and B viruses including avian" exact="influenza" post="viruses H5N1 and H7N9 ( Sidwell et al., 2007;"/>
 <result pre="loss, and survival in mice infected with a pandemic H1N1" exact="influenza" post="virus ( Tarbet et al., 2012) or with an"/>
 <result pre="influenza virus ( Tarbet et al., 2012) or with an" exact="avian influenza" post="virus H5N1 ( Smee et al., 2010). Favipiravir is"/>
 <result pre="virus ( Tarbet et al., 2012) or with an avian" exact="influenza" post="virus H5N1 ( Smee et al., 2010). Favipiravir is"/>
 <result pre="but its use is restricted to patients infected with an" exact="influenza" post="virus resistant to NAI or in the event of"/>
 <result pre="efficacy and safety of favipiravir for the treatment of uncomplicated" exact="influenza" post="infection in adults have been completed but the results"/>
 <result pre="to determine the pharmacokinetics of favipiravir in patients with severe" exact="influenza" post="is reported as active but not currently recruiting with"/>
 <result pre="et al., 2016) , in vitro escalation studies showed that" exact="influenza" post="viruses can adapt to low concentration of the compound"/>
 <result pre="concentration of the compound which highlights the potential for some" exact="influenza" post="virus strains to possibly develop resistance ( Ormond et"/>
 <result pre="acids are the primary receptors for binding and entry of" exact="influenza" post="viruses. Fludase works by removing sialic receptors from the"/>
 <result pre="broad-spectrum anti-influenza antiviral with potent antiviral activity against human and" exact="avian influenza" post="viruses with no cellular toxicity ( Triana-Baltzer et al.,"/>
 <result pre="anti-influenza antiviral with potent antiviral activity against human and avian" exact="influenza" post="viruses with no cellular toxicity ( Triana-Baltzer et al.,"/>
 <result pre="In vivo studies showed that mice can be rescued from" exact="influenza" post="infection after treatment with fludase, including after infection with"/>
 <result pre="determine the effective dose in healthy adult participants with laboratory-confirmed" exact="influenza" post="(NCT01037205), it was observed that treatment with fludase significantly"/>
 <result pre="has shown activity against a broad range of viruses including" exact="influenza" post="viruses ( Belardo et al., 2015; Tilmanis et al.,"/>
 <result pre="2017; Stachulski et al., 2018). The mechanism of action against" exact="influenza" post="virus is achieved by impairing the trafficking of the"/>
 <result pre="Preclinical studies demonstrated an antiviral activity against different strains of" exact="influenza" post="A, and B viruses in vitro including avian influenza"/>
 <result pre="strains of influenza A, and B viruses in vitro including" exact="avian influenza" post="viruses ( Sleeman et al., 2014). There are not"/>
 <result pre="of influenza A, and B viruses in vitro including avian" exact="influenza" post="viruses ( Sleeman et al., 2014). There are not"/>
 <result pre="facilitating the advancement of this drug as a treatment for" exact="influenza" post="virus infection ( Rossignol, 2009). A phase 2b/3 clinical"/>
 <result pre="and efficacy of NTZ in the treatment of acute uncomplicated" exact="influenza" post="established that treatment with 300 mg twice a day"/>
 <result pre="( Stachulski et al., 2018) in the treatment of uncomplicated" exact="influenza" post="was concluded in March 2019 but results have not"/>
 <result pre="with activity against RSV and other RNA viruses such as" exact="hepatitis" post="C and Zika viruses ( Antonini et al., 2018;"/>
 <result pre="premature infants as well as in high-risk children with chronic" exact="lung disease" post="of prematurity ( Abarca et al., 2009; Oâ€™Brien et"/>
 <result pre="of this siRNA were observed in reducing the risk of" exact="bronchiolitis" post="obliterans syndrome ( Gottlieb et al., 2016). Further evaluations"/>
 <result pre="2017). Symptoms may include respiratory illness that can lead to" exact="acute respiratory distress syndrome" post="( Assiri et al., 2013; Memish et al., 2013)"/>
 <result pre="et al., 2013) and digestive symptoms including nausea, vomiting, and" exact="diarrhea" post="( Centers for Disease Control and Prevention, 2017) with"/>
 <result pre="and their use is based on knowledge obtained during the" exact="severe acute respiratory syndrome" post="(SARS) outbreak in 2003 and the recent influenza pandemic"/>
 <result pre="acute respiratory syndrome (SARS) outbreak in 2003 and the recent" exact="influenza" post="pandemic in 2009 ( Mo and Fisher, 2016). Furthermore,"/>
 <result pre="plasma) has shown beneficial effects in outbreaks of SARS and" exact="influenza" post="virus infections ( Al-Tawfiq et al., 2017). Studies in"/>
 <result pre="review summarizes the current antivirals available for the treatment of" exact="influenza" post="and RSV along with potential new therapies for these"/>
 <result pre="1). Greater advances have been achieved in the field of" exact="influenza" post="antivirals. Currently, three groups of drugs are approved for"/>
 <result pre="therapeutics currently under development (clinical trials), for the treatment of" exact="influenza" post="virus, respiratory syncytial virus (RSV), and Middle East respiratory"/>
 <result pre="Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute" exact="influenza" post="infections . Front. Microbiol. 7: 450. 10.3389/fmicb.2016.00450 , PMID:"/>
 <result pre="MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated" exact="influenza" post=". Antimicrob. Agents Chemother. 62: e00694-18. 10.1128/AAC.00694-18 30150460 Al-Tawfiq"/>
 <result pre="( 2015). Synergistic effect of nitazoxanide with neuraminidase inhibitors against" exact="influenza" post="A viruses in vitro . Antimicrob. Agents Chemother. 59,"/>
 <result pre="DAS181, a novel sialidase fusion protein, protects mice from lethal" exact="avian influenza" post="H5N1 virus infection . J. Infect. Dis. 196, 1493â€“"/>
 <result pre="a novel sialidase fusion protein, protects mice from lethal avian" exact="influenza" post="H5N1 virus infection . J. Infect. Dis. 196, 1493â€“"/>
 <result pre="of charge on antiviral potency and kinase activity of azaindole-based" exact="influenza" post="PB2 inhibitors . Bioorg. Med. Chem. Lett. 25, 1990â€“"/>
 <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunit . Antimicrob. Agents Chemother. 59,"/>
 <result pre="of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of" exact="influenza" post="PB2 . J. Med. Chem. 57, 6668â€“ 6678. 10.1021/jm5007275"/>
 <result pre="Berlin, Heidelberg: Springer-Verlag), 3â€“ 38. Davidson S. ( 2018). Treating" exact="influenza" post="infection, from now and into the future. Front. Immunol."/>
 <result pre="an anti-influenza A monoclonal antibody, in healthy subjects challenged with" exact="influenza" post="A virus in a phase IIa randomized trial ."/>
 <result pre="( 2011). A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science 333, 843â€“ 850. 10.1126/science.1204839 , PMID:"/>
 <result pre="D. Ferguson S. et al. . ( 2018). A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
 <result pre="Ferkol T. Schraufnagel D. ( 2014). The global burden of" exact="respiratory disease." post="Ann. Am. Thorac. Soc. 11, 404â€“ 406. 10.1513/AnnalsATS.201311-405PS 24673696"/>
 <result pre="marboxil and a neuraminidase inhibitor in a mouse model of" exact="influenza" post="A virus infection . J. Antimicrob. Chemother. 74, 654â€“"/>
 <result pre="al. . ( 2005). Mechanism of action of T-705 against" exact="influenza" post="virus. Antimicrob. Agents Chemother. 49, 981â€“ 986. 10.1128/AAC.49.3.981-986.2005 ,"/>
 <result pre="D. et al. . ( 2016). ALN-RSV01 for prevention of" exact="bronchiolitis" post="obliterans syndrome after respiratory syncytial virus infection in lung"/>
 <result pre="C. et al. . ( 2018). Baloxavir Marboxil for uncomplicated" exact="influenza" post="in adults and adolescents. N. Engl. J. Med. 379,"/>
 <result pre="the I38T PA substitution as a resistance marker for next-generation" exact="influenza" post="virus endonuclease inhibitors . MBio 9: e00430-18. 10.1128/mBio.01868-18 ,"/>
 <result pre="2016). Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes. Cell 166, 596â€“ 608. 10.1016/j.cell.2016.05.073 , PMID:"/>
 <result pre="postexposure use of human monoclonal antibody against H5N1 and H1N1" exact="influenza" post="virus in mice: viable alternative to oseltamivir . J."/>
 <result pre="2006). Sialidase fusion protein as a novel broad-spectrum inhibitor of" exact="influenza" post="virus infection. Antimicrob. Agents Chemother. 50, 1470â€“ 1479. 10.1128/AAC.50.4.1470-1479.2006"/>
 <result pre="An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic" exact="influenza" post="A virus subtype H7N9 and protects mice from lethality"/>
 <result pre="A. Sleeman K. et al. ( 2015). Characterization of drug-resistant" exact="influenza" post="A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan"/>
 <result pre="of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human" exact="influenza" post="A virus challenge model . Antimicrob. Agents Chemother. 61:"/>
 <result pre="DAS181, a novel host directed antiviral for the treatment of" exact="influenza" post="infection . J. Infect. Dis. 206, 1844â€“ 1851. 10.1093/infdis/jis622"/>
 <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodies . Cell Host Microbe 14, 93â€“ 103."/>
 <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunit . Antiviral Res. 160, 109â€“"/>
 <result pre="( 2017). The combined effect of oseltamivir and favipiravir on" exact="influenza" post="A virus evolution. Genome Biol. Evol. 9, 1913â€“ 1924."/>
 <result pre="determination of neuraminidase-active foci in cell monolayer cultures infected with" exact="influenza" post="or Newcastle disease virus . J. Virol. 6, 556â€“"/>
 <result pre="MEDI8852 prevents and controls disease and limits transmission of pandemic" exact="influenza" post="viruses . J. Infect. Dis. 216, 356â€“ 365. 10.1093/infdis/jix292"/>
 <result pre="S. Newall A. T. ( 2018). Economic burden of seasonal" exact="influenza" post="in the United States. Vaccine 36, 3960â€“ 3966. 10.1016/j.vaccine.2018.05.057"/>
 <result pre="2008). Structure and mechanism of the M2 proton channel of" exact="influenza" post="A virus. Nature 451, 591â€“ 595. 10.1038/nature06531 , PMID:"/>
 <result pre="25900158 Shaw M. L. ( 2017). The next wave of" exact="influenza" post="drugs. ACS Infect. Dis. 3, 691â€“ 694. 10.1021/acsinfecdis.7b00142 ,"/>
 <result pre=". ( 2007). Efficacy of orally administered T-705 on lethal" exact="avian influenza" post="A (H5N1) virus infections in mice . Antimicrob. Agents"/>
 <result pre="( 2007). Efficacy of orally administered T-705 on lethal avian" exact="influenza" post="A (H5N1) virus infections in mice . Antimicrob. Agents"/>
 <result pre="M. et al. . ( 2014). Antiviral susceptibility of variant" exact="influenza" post="A(H3N2)v viruses isolated in the United States from 2011"/>
 <result pre="S. M. ( 2016). Activities of JNJ63623872 and oseltamivir against" exact="influenza" post="A H1N1pdm and H3N2 virus infections in mice ."/>
 <result pre="Effects of the combination of favipiravir (T-705) and oseltamivir on" exact="influenza" post="A virus infections in mice . Antimicrob. Agents Chemother."/>
 <result pre="2018). Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the" exact="influenza" post="A virus . Future Med. Chem. 10, 851â€“ 862."/>
 <result pre="Furuta Y. et al. . ( 2016). Antiviral susceptibility of" exact="influenza" post="viruses isolated from patients pre- and post-administration of favipiravir"/>
 <result pre="al. . ( 2015). Characterization of a large cluster of" exact="influenza" post="A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the"/>
 <result pre="A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014" exact="influenza" post="season in Japan . Antimicrob. Agents Chemother. 59, 2607â€“"/>
 <result pre="Fujisaki S. Shirakura M. et al. ( 2018). Susceptibility of" exact="influenza" post="viruses to the novel cap-dependent endonuclease inhibitor Baloxavir Marboxil"/>
 <result pre="Combinations of favipiravir and peramivir for the treatment of pandemic" exact="influenza" post="A/California/04/2009 (H1N1) virus infections in mice . Antiviral Res."/>
 <result pre="Cain D. Sasisekharan V. Sasisekharan R. ( 2014). Broadly neutralizing" exact="influenza" post="hemagglutinin stem-specific antibody CR8020 targets residues that are prone"/>
 <result pre="Hurt A. C. ( 2017). The susceptibility of circulating human" exact="influenza" post="viruses to tizoxanide, the active metabolite of nitazoxanide ."/>
 <result pre="2018). Pimodivir treatment in adult volunteers experimentally inoculated with live" exact="influenza" post="virus: a phase IIa, randomized, double-blind, placebo-controlled study ."/>
 <result pre="DAS181, a sialidase fusion protein, protects human airway epithelium against" exact="influenza" post="virus infection: an in vitro pharmacodynamic analysis . J."/>
 <result pre="Belser J. A. et al. . ( 2009). Novel pandemic" exact="influenza" post="A(H1N1) viruses are potently inhibited by DAS181, a sialidase"/>
 <result pre="et al. . ( 2011). Phenotypic and genotypic characterization of" exact="influenza" post="virus mutants selected with the sialidase fusion protein DAS181"/>
 <result pre="&quot; S-033188, a small molecule inhibitor of cap-dependent endonuclease of" exact="influenza" post="A and B virus, leads to rapid and profund"/>
 <result pre="viral load reduction &quot; in Options for the control of" exact="influenza" post="IX ( Chicago, USA: ISIRV), 77. Van Heeke G."/>
 <result pre="J. ( 2009). Solution structure and functional analysis of the" exact="influenza" post="B proton channel. Nat. Struct. Mol. Biol. 16, 1267â€“"/>
 <result pre="antibody to RSV and other respiratory viruses for use in" exact="primary immunodeficiency disease" post="and other immune compromised populations . Expert Rev. Clin."/>
 <result pre="Yamada S. et al. . ( 2013). Characterization of H7N9" exact="influenza" post="A viruses isolated from humans. Nature 501, 551â€“ 555."/>
 <result pre="L. Li L. J. ( 2015). Successful treatment of avian-origin" exact="influenza" post="A (H7N9) infection using convalescent plasma . Int. J."/>
 <result pre="Lee S. M. ( 2018). Advancements in host-based interventions for" exact="influenza" post="treatment. Front. Immunol. 9: 1547. 10.3389/fimmu.2018.01547 30042762 Zenilman J."/>
</results>
